Option chain shows key data for Orchestra BioMed Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Orchestra BioMed Hldgs.

Orchestra BioMed Hldgs (NASDAQ:OBIO) Stock, Option Chain

Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATOM

DGLY

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FUFU

IMTE

MULN

MURA

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PROP

PSIX

SAGE

STFS

TNON

TOPP

TRSG

VVPR

XHLD

Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Analysts Pick 4 Stocks Poised for Growth, Including Tech Giants Microsoft And Meta

Initiation

Analyst Ratings

CRVS

KOPN

NWFL

This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Biotech

Earnings

General

ALKS

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) shares ended the last trading session 7.3% higher at $6.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock&#39;s 12.8% gain over the past four weeks.

Orchestra BioMed Holdings, Inc. Stock Jumps 7.3%: Will It Continue to Soar?

Orchestra BioMed Holdings Inc

Health Care

Press Releases

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Management

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

GELS

PNPNF

PRSO

TIVC

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CytoSorbents

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Orchestra BioMed Hldgs

Orchestra BioMed Hldgs (OBIO) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell